What did BioDerm pay for Argentum Medical?

BioDerm acquired Argentum Medical for $200.0M in 2023 (14.8x EBITDA). Target EBITDA was approximately $13.5M.

What does Argentum Medical do?

Argentum Medical is a medical devices business.

What multiple did BioDerm pay for Argentum Medical?

14.8x EBITDA, based on disclosed deal value of $200.0M and disclosed financials.

M&A TRANSACTION · 2023

Argentum Medical acquired by BioDerm

$200.0M· 14.8x EBITDA

Target

Argentum Medical

Acquirer

BioDerm

Strategic buyer

Disclosed financials at time of acquisition

Revenue

—

EBITDA

$13.5M

Deal Value

$200.0M

EV/EBITDA

14.8x

Context

This $200.0M acquisition of Argentum Medical by BioDerm sits in the medical devices sub-vertical. The 14.8x EBITDA multiple paid in 2023 can be compared against the population median for medical devices transactions of similar size on our Medical Devices valuation hub. BioDerm is acquiring as a strategic buyer; see how strategic acquirers typically price medical devices businesses on our Medical Devices strategic buyer-pool page.

Source

Data sourced from Press reporting. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology

Value your own medical devices

Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.

Compare your business to the Argentum Medical acquisition.

Citation: ExitValue.ai. (2023). Argentum Medical acquired by BioDerm. https://exitvalue.ai/deals/argentum-medical-acquired-by-bioderm-hc-2023-0052